AtaiBeckley Inc Dossier
Qualitative Analysis
Business overview
AtaiBeckley Inc. (formerly known as Atai Beckley N.V. prior to its corporate redomiciliation from the Netherlands to Delaware, USA in December 2025) is a leading clinical-stage biopharmaceutical company dedicated to transforming patient outcomes by developing rapid-acting, durable, and convenient mental health treatments. The company was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley operates at the intersection of psychedelic science and neuropharmacology, advancing a robust pipeline of investigational psychedelic-based neuroplastogens and related therapeutics. Its lead clinical candidates include BPL-003 (an intranasal formulation of mebufotenin benzoate) for treatment-resistant depression (TRD), VLS-01 (a buccal film formulation of DMT) for TRD, and EMP-01 (an oral formulation of R-MDMA) for social anxiety disorder.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing BPL-003 (intranasal mebufotenin benzoate) into Phase 3 pivotal trials for treatment-resistant depression (TRD) following a successful End-of-Phase 2 meeting with the FDA.
Expected impact: Aims to establish BPL-003 as a rapid-acting, durable, and convenient interventional psychiatry treatment that fits within existing 2-hour clinic workflows.
Developing VLS-01, an oral transmucosal buccal film formulation of N,N-Dimethyltryptamine (DMT), for patients with treatment-resistant depression (TRD).
Expected impact: Provides a highly scalable, patient-friendly formulation of DMT designed to offer rapid therapeutic effects with short in-clinic times.
A community-focused initiative offering $60,000 in total grants ($20,000 each to three non-profit organizations) to support mental health community support, education, stigma reduction, and ecosystem innovation.
Expected impact: Strengthens the company's mission-driven brand, builds trust, and supports independent initiatives that influence real-world patient outcomes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine the assets, clinical expertise, and vision of atai Life Sciences and Beckley Psytech, creating a global leader in rapid-acting, short-duration psychedelic therapies. The transaction fully internalizes Beckley's Phase 3-ready lead asset BPL-003 and VLS-01 into the combined company's pipeline.
Financial impact: Beckley shareholders (excluding atai) were issued 103,000,066 ordinary shares of atai, representing approximately 28% of the combined company. The transaction widened near-term R&D and G&A expenses but consolidated a robust cash runway extending into 2029.
Strategic Partnerships
Psilera licensed a DMT patent portfolio to AtaiBeckley, expanding the company's intellectual property moat and supporting its long-term pipeline expansion in next-generation neuroplastogens.
Terms: Financial terms of the licensing agreement were not publicly disclosed.